-
2022-502007-30-00
5
2023-11-07
Kidney transplant
-
2022-502597-16-00
9
2023-10-27
Intermediate or High-risk Primary or Secondary
Myelofibrosis
-
2022-501515-14-00
5
2023-09-29
Newly Diagnosed Multiple Myeloma (NDMM)
-
2022-502019-12-00
5
2023-09-14
acute myeloid leukemia
-
2022-501810-77-00
5
2023-09-01
Relapsed or Refractory Marginal Zone Lymphoma
-
2022-500974-33-00
5
2023-08-12
acute venous thromboembolism event
-
2022-500967-11-00
5
2023-07-06
Previously Untreated Metastatic or Unresectable Melanoma
-
2024-512999-35-00
4
2023-06-23
Patients with HER 2 negative locally advanced, recurrent or metastatic
-
2024-513243-85-00
4
2023-02-03
Adult medulloblastoma
-
2022-500197-34-01
4
2022-11-03
Megalencephaly-CApillary malformation Polymicrogyria syndrome
-
2022-500295-60-00
4
2022-09-15
Acute Myeloid Leukemia
-
2022-502687-20-00
4
2022-09-14
Wilms tumor
-
2024-511899-32-00
10
2022-08-31
Dermatomyositis; Baricitinib in patients with relapsing or naïve derma
-
2024-515354-24-00
9
2022-05-18
Low risk myelodysplastic syndrom without RS having failed or being ine
-
2024-515945-40-00
10
2022-05-02
Non small cell lung cancer
-
2023-506081-31-00
5
2022-03-29
Traumatic Injury
-
2024-515075-36-00
6
2021-12-01
kidney transplantion -Epstein Barr virus
-
2024-514025-30-00
4
2021-03-25
Ocular conservative treatment for retinoblastoma
-
2024-512229-10-00
4
2021-02-04
Takayasu arteritis
-
2024-514156-33-00
5
2019-08-20
Patients in remission for granulomatosis with polyangiitis (GPA,
Wegen
-
2024-511862-35-00
4
2019-07-19
Adults with non-contrast-enhancing diffuse brainstem gliomas with non-
-
2022-501254-10-00
5
2018-08-24
Advanced tumors
-
2024-518578-15-00
5
2018-02-05
Is to demonstrate a non inferior efficacy of azithromycin and so the p
-
2024-516103-16-00
4
2015-12-04
Acute Lymphoblastic Leukemia (ALL) in younger adults (18-59 years)